Abstract:Description NKG2C+CD8+ T cells, found in 40% of HCMV-seropositive individuals, have lost BCL11B expression and adopt an innate-like identity. T cell identity theft Human cytomegalovirus (HCMV) infection drives expansion of NK cells expressing the activating receptor NKG2C, which also serves as a receptor for HLA-E. Sottile et al. demonstrate that a subset of CD8+ T cells expressing NKG2C are also expanded in HCMV-seropositive individuals, acquire transcriptional features of NK cells, and display a restricted TCR repertoire. NKG2C+CD8+ T cells down-regulated the transcription factor BCL11B, deletion of which enabled in vitro generation of phenotypically similar T cells. In addition, NKG2C+ T cells were resistant to PD-1 induction and displayed high levels of cytotoxicity against target cells, highlighting their potential for adoptive cell therapy applications. These findings identify NKG2C+CD8+ T cells as HCMV-expanded innate-like T cells and provide insight into cells residing at the interface of innate and adaptive immunity. CD8+ T cells not only are critical mediators of adaptive immunity but also may exhibit innate-like properties such as surface expression of NKG2C, an activating receptor typically associated with natural killer (NK) cells. We demonstrate that, similar to NK cells, NKG2C+TCRαβ+CD8+ T cells are associated with prior human cytomegalovirus (HCMV) exposure. In addition to expressing several NK cell markers such as CD56 and KIR, NKG2C+CD8+ T cells are oligoclonal and do not up-regulate PD-1 even in response to persistent activation. Furthermore, we found that NKG2C+CD8+ T cells from some individuals exhibited strong effector function against leukemia cells and HCMV-infected fibroblasts, which was dictated by both NKG2C and TCR specificity. Transcriptomic analysis revealed that the transcription factor BCL11B, a regulator of T cell developmental fate, is down-regulated in NKG2C+CD8+ T cells when compared with conventional NKG2C−CD8+ T cells. BCL11B deletion in conventional CD8+ T cells resulted in the emergence of a similar innate-like CD56+CD94+DAP12+NKG2C+CD45RA+CCR7−PD-1−/low T cell population with activity against HLA-E+ targets. On the basis of their intrinsic capacity to recognize diseased cells coupled with lack of PD-1 induction, NKG2C+CD8+ T cells represent a lymphocyte population that resides at the boundary between innate and adaptive immunity, presenting an attractive alternative for cellular therapy, including CAR T cell–based therapies.

Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity